DDW the quarterly business review of drug discovery & development
dr ug discov er y wo r l d
Novel assay development and drug screening for known and orphan GPCRs: the PathHunter® Arrestin, internalisation and heterodimerisation assays
Register now!
http://tiny.cc/DDW-GPCRWebinar DATE: May 24th, 2011 TIME: 7am PST
G protein-coupled receptors (GPCRs) are the most common molecular drug targets. During early drug discovery, the design and implementation of a high-throughput GPCR functional assay is critical to facilitate screening of large compound libraries required to identify novel drug candidates.
A wide variety of assays are currently available for analysing GPCR signalling events, many of them based on second messenger analysis. PathHunter -Arrestin assays are unique in that they provide a direct measure of GPCR activation by detecting the binding of -Arrestin to the GPCR of interest. Because Arrestin recruitment occurs independent of G-protein coupling, these assays offer a powerful and universal screening platform that can be used with virtually any Gi-, Gs-, or Gq-coupled receptors making them ideal for surrogate ligand discovery, de-orphanisation and receptor profiling.
During the webinar you will learn about the features of the PathHunter technology the ease of implementation of this technology from assay development to full deck HTS screening. We will discuss the utility of the platform for receptor de-orphanisation and interrogation novel GPCR heterodimers.
What will be covered • Description of PathHunter Arrestin technology • Novel application of the technology to studying GPCR heterodimers • Utility of the G-protein independent read-out for interrogating orphan GPCR receptors
Who should attend • Scientists involved in GPCR drug discovery including assay development, high-throughput screening, lead optimisation and pre-clinical
• High-throughput screening scientists interested in ligand fishing and receptor de-orphanisation • Researchers developing novel cell-based assays for GPCRs (heterodimers, internalisation) • Medicinal chemists and biologists optimizing leads from a primary screening campaign • Pharmacologists and cell biologists working in life science laboratories
Panelists include Layton H. Smith, Director of High Throughput Screening, Sanford-Burnham Medical Research Institute Xavier Leroy, Associate Director & Project Leader, Drug Discovery Group, Actelion Pharmaceuticals Tom Wehrman, PhD Senior Research Director, DiscoveRx Corporation
Produced with support from REGISTER TODAY at
http://tiny.cc/DDW-GPCRWebinar PANELISTS
Layton H. Smith, Director of High Throughput Screening, Sanford- Burnham Medical Research Institute
Xavier Leroy, Associate Director & Project Leader, Drug Discovery Group, Actelion Pharmaceuticals
Tom Wehrman, PhD, Senior Research Director, DiscoveRx Corporation
MODERATOR
Robert Jordan, Publisher and Editor-in-Chief, Drug Discovery World
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80